Dr. Arezou Ghazani is the Director of Clinical Genomics at Brigham Genomic Medicine and a faculty member at Harvard University. She is the Founder and Chair of the INT²GRATE | Oncology Consortium, an international and multi-institutional collaboration dedicated to advancing precision oncology through the integration of constitutional and tumor-derived data (int2grateoncology.org). INT²GRATE is an innovative platform that combines tumor signature profiles with clinical genetic information to identify clinically actionable germline alterations in cancer patients. Dr. Ghazani also serves as the Executive Director of several multi-institutional clinical genomic programs at Brigham and Women's Hospital, focusing on investigating the clinical actionability of large-scale genome variants across diverse populations with cancer and pediatric disorders. The overarching goal is to integrate comprehensive genomic information into routine patient care, enhancing clinical decision-making and advancing precision oncology. Dr. Ghazani has earned her MSc and PhD from University of Toronto and completed both her Medical Genetics and Research Fellowships at Harvard Medical School. She is board-certified by the American Board of Medical Genetics and Genomics.